New Stock News | Zhengxiang Pharma Submitted Application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on January 30, Zhengxiang Medicine (Nanjing) Group Co., Ltd. (hereinafter referred to as "Zhengxiang Medicine") has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CICC as its exclusive sponsor. According to the prospectus, Zhengxiang Medicine is a commercially stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies to address unmet medical needs in the fields of viral infectious diseases, oncology, and inflammatory diseases. The core product of Zhengxiang Medicine, Masequovir Tablets, is an inhibitor of the acidic protein (PA) endonuclease of the influenza virus. It obtained approval from the National Medical Products Administration ("NMPA") for a new drug application ("NDA") for the treatment of adult influenza in July 2025, and the company is expanding its indications to adolescent patients and post-exposure prevention. Utilizing commercial drug assets and a comprehensive small molecule drug development platform, Zhengxiang Medicine has developed six drug asset pipelines, including its commercial Masequovir tablets, a late-stage clinical Masequovir dry powder for children with influenza, ZX-8177 for the treatment of solid tumors (phase I clinical stage), and a drug for human papillomavirus ("HPV") infection in the IND application stage. Zhengxiang Medicine also has two preclinical candidate drugs for herpes simplex virus ("HSV") infection and autoimmune diseases.